Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer

Ovarian Cancer Clinical Trial

Official title:

High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Bone Marrow Transplantation for Relapsed and Refractory Germ Cell Cancer: A Phase II Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00002943
• Other study ID #: CDR0000065392
• Secondary ID: CCCWFU-95193NCI-
• Status: Completed
• Phase: Phase 2
• Start date: February 1993
• Est. completion date: August 2007

Study information

• Verified date: August 2018
• Source: Wake Forest University Health Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous bone marrow transplantation may help the body kill more tumor cells.

PURPOSE: Phase II trial to study the effects of high doses of carboplatin, etoposide, and cyclophosphamide followed by autologous bone marrow transplantation in patients with relapsed or refractory germ cell cancer and other chemotherapy-sensitive solid tumors.

Description:

OBJECTIVES:

• Investigate the response rate, duration of response, survival, time to marrow reconstitution, and toxicity of two successive cycles of high dose carboplatin, etoposide, and cyclophosphamide chemotherapy and ABMT in patients with relapsed and refractory germ cell cancer or other chemotherapy-sensitive solid tumors.

• Further define the pretransplant characteristics of patients and their disease that might influence the outcome of this therapy.

OUTLINE: Patients receive carboplatin and etoposide for 5 days and cyclophosphamide for 2 days prior to ABMT.

At day 60 following ABMT, if the patient has a complete response (CR) or partial response (PR) and nonhematologic toxicity is no greater than grade 2, a second ABMT course is given when hematologic parameters and other criteria are acceptable. If there is no CR or PR and/or nonhematologic toxicity exceeds grade 2, a second ABMT is not given.

After ABMT patients are followed until disease progression or death.

PROJECTED ACCRUAL: Ten patients will be accrued for this pilot study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: August 2007
• Est. primary completion date: October 2003
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 120 Years

Eligibility

DISEASE CHARACTERISTICS:

• Histologically confirmed, measurable germ cell cancer relapsed or refractory after frontline therapy with cisplatin and etoposide-containing chemotherapy

• Other chemotherapy-sensitive solid tumors eligible (as of 06/11/97)

• Possibility of residual mass representing benign teratoma must be excluded

• Elevated serum tumor markers only are acceptable if possibilities of false-positive serum tumor markers or sanctuary disease have been excluded

• Also eligible after two to four cycles of conventional dose salvage chemotherapy, regardless of response

• No CNS or bone marrow involvement

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Performance status:

• Karnofsky 60-100%

Life expectancy:

• Greater than 2 months

Hematopoietic:

• Platelet count at least 100,000/mm3

• Neutrophil count at least 1,500/mm3

Hepatic:

• Bilirubin, alkaline phosphatase, SGOT, and SGPT less than 3 times upper limit of normal, unless due to disease

Renal:

• Creatinine less than 1.5 times upper limit of normal

• Creatinine clearance at least 60 ml/min

Cardiovascular:

• Ventricular ejection fraction at least 45%

• No uncontrolled or severe cardiovascular disease including recent myocardial infarction, congestive heart failure, angina, life-threatening arrhythmia, or hypertension

Pulmonary:

• DLCO and spirometry greater than 50% of predicted

Other:

• Not HIV positive

• No active peptic ulcer

• No uncontrolled diabetes mellitus

• No active infection

• No previous or concomitant malignancy other than curatively treated basal or squamous cell carcinoma of the skin

• Not HBsAG positive

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior high-dose carboplatin, etoposide, or cyclophosphamide

Endocrine therapy:

• Not specified

Radiotherapy:

• Not specified

Surgery:

• Not specified

Related Conditions & MeSH terms

• Extragonadal Germ Cell Tumor
• Neoplasms
• Neoplasms, Germ Cell and Embryonal
• Ovarian Cancer
• Testicular Germ Cell Tumor
• Testicular Neoplasms
• Unspecified Adult Solid Tumor, Protocol Specific

Intervention

Drug:
• carboplatin

• cyclophosphamide

• etoposide

Procedure:
• autologous bone marrow transplantation

Locations

Country	Name	City	State
United States	Comprehensive Cancer Center at Wake Forest University	Winston-Salem	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Wake Forest University Health Sciences	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To investigate the response rate High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation		45 days
Secondary	evaluate toxicity of High Dose Carboplatin, Etoposide, Cyclophosphamide and Autologous Transplantation		45 days